Glycogen synthase kinase-3β inhibition induces nuclear factor-κB-mediated apoptosis in pediatric acute lymphocyte leukemia cells

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Hu, Yanni ^a   Gu, Xiaoyan ^a   Li, Ruiyan ^a   Luo, Qing ^a   Xu, Youhua ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR RELA; BIRC5 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MICROTUBULE ASSOCIATED PROTEIN;

ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL NUCLEUS; CHILD; CHILDHOOD LEUKEMIA; CHINA; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DOWN REGULATION; ENZYME INHIBITION; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ACUTE LYMPHOBLASTIC LEUKEMIA; BIOSYNTHESIS; CELL CULTURE; CELL SEPARATION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, WESTERN; CELL SEPARATION; CELLS, CULTURED; CHILD; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NF-KAPPA B; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 78649321570     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-154     Document Type: Article

References (24)

1. Treatment of acute lymphoblastic leukemia. CH Pui WE Evans, N Engl J Med 2006 354 166 178 10.1056/NEJMra052603 16407512
2. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. CH Pui S Jeha, Nat Rev Drug Discov 2007 6 149 165 10.1038/nrd2240 17268486
3. The role of glycogen synthase kinase-3β in insulin resistance and type 2 diabetes. O Kaidanovich H Eldar-Finkelman, Expert Opin Ther Targets 2002 6 555 561 10.1517/14728222.6.5.555 12387679
4. GSK-3β: tricks of the trade for a multi-tasking kinase. BW Doble JR Woodgett, J Cell Sci 2003 116 1175 1186 10.1242/jcs.00384 12615961
5. Glycogen synthase kinase 3 in MLL leukemia maintenance and targeted therapy. W Zhong SS Kevin M Mark P Obdulio CPS Tim LC Michael, Nature 2008 455 1205 1210 10.1038/nature07284 18806775
6. Genetic deletion of glycogen synthase kinase-3β abrogates activation of IB kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by Tumor Necrosis Factor. Y Takada X Fang MS Jamaluddin DB Douglas BA Bharat, J Biol Chem 2004 279 39541 54 10.1074/jbc.M403449200 15252041
7. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. PH Klaus L Juan AR Elizabeth ST Ming J Ou RW James, Nature 2000 406 86 90 10.1038/35017574 10894547
8. Glycogen synthase kinase-3β participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. VO Andrei EF Martin NS Doris AU Raul DB Daniel, Cancer Res 2005 65 6 2076 2081 10.1158/0008-5472.CAN-04-3642 15781615
9. Inhibition of glycogen synthase kinase-3β activity leads to epigenetic silencing of nuclear factor B target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. VO Andrei DB Nancy EF Martin EK Neil DB Daniel, Blood 2007 110 735 742 10.1182/blood-2006-12-060947 17463171
10. The expression of 70 apoptosis genes in relation to lineage, genetic subtype,cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. H Amy LB Monique XM Renee HC Meyling C Cheng MK Karin EJ Gritta G Ulrich BG Ulrike EE William P Rob, Blood 2006 107 769 776 10.1182/blood-2005-07- 2930 16189266
11. Selective small molecule inhibitors of glycogen synthase kinase-3β modulate glycogen metabolism and gene transcription. PC Matthew AC Ainsley AC Darren LC Stacey WY John JP Nigel LR Oliver JM Gregory SC Paul RC Lynne M David JB Murray H David WW Robert GS David JM Kenneth DR Alastair CH Julie, Chem Biol 2000 7 793 803 10.1016/S1074-5521(00)00025-9 11033082
12. A molecular mechanism for the effect of lithium on development. SK Peters AM Douglas, Proc Natl Acad Sci 1996 93 16 8455 8459 10.1073/pnas.93.16.8455 8710892
13. Glycogen Synthase Kinase-3Β Inhibition Preserves Hematopoietic Stem Cell Activity and Inhibits Leukemic Cell Growth. H Tiffany AO Tracey K Robert L Robert S Sylvie S Emma S Geoff D Alla, Stem Cell 2008 26 1288 1297 10.1634/stemcells.2007-0600
14. Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3βbeta in colorectal cancer cells. JC Ghosh DC Altieri, Clin Cancer Res 2005 11 4580 4588 10.1158/1078-0432.CCR-04-2624 15958644
15. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. S Abbas O Andrei WY Zhi Z Bin HM Mohammad DB Daniel M Masayoshi T Yutaka M Toshinari, Biochem Biophys Res Commun 2005 334 1365 1373 10.1016/j.bbrc.2005.07.041 16043125
16. Inhibition of glycogen synthase kinase-3β represses androgen receptor activity and prostate cancer cell growth. M Mazor Y Kawano H Zhu J Waxman RM Kypta, Oncogene 2004 23 7882 7892 10.1038/sj.onc.1208068 15361837
17. Aberrant nuclear accumulation of glycogen synthase kinase-3β in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. VO Andrei EF Martin NB Vladimir CS Thomas TC Suresh DB Daniel, Clin Cancer Res 2006 12 5074 5081 10.1158/1078-0432.CCR-06-0196 16951223
18. Phosphorylation of serine 468 by GSK-3βbeta negatively regulates basal p65 NF-κB activity. H Buss A Dorrie ML Schmitz R Frank M Livingstone K Resch M Kracht, J Biol Chem 2004 279 49571 49574 10.1074/jbc.C400442200 15465828
19. Nuclear factor-B in cancer development and progression. Michael Karin, Nature 2006 441 431 436 10.1038/nature04870 16724054
20. Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Baud Véronique Michael Karin, Nature 2009 8 33 40 10.1038/nrd2781
21. A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. FD Toni C Racaud-Sultan G Chicanne MV Mas C Cariven F Mesange JP Salles C Demur M Allouche B Payrastre S Manenti L Ysebaert, Oncogene 2006 25 3113 3122 10.1038/sj.onc.1209346 16407823
22. Nuclear factor-kappaB: the enemy within. BB Aggarwal, Cancer Cell 2004 6 203 208 10.1016/j.ccr.2004.09.003 15380510
23. Expression of the NF-κB targets BCL2 and BIRCS/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. L Tracey A Perez-Rosado MJ Artiga FI Camacho A Rodriguez N Martinez E Ruiz-Ballesteros M Mollejo B Martinez M Cuadros JF Garcia M Lawler MA Piris, J Pathol 2005 206 123 134 10.1002/path.1768 15880597
24. Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. BH Kuzhuvelil BK Ajaikumar SA Kwang A Preetha K Sunil G Sushovan BA Bharat, Blood 2009 113 2003 2013 10.1182/blood-2008-04-151944 18952893